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Background. Although human immunodeficiency virus (HIV)–infected persons are at increased risk for major cardiovascular
events, short-term prognosis after these events is unclear.
Methods. To determine the association between HIV infection and acute myocardial infarction (AMI) and stroke outcomes, we
analyzed hospital discharge data from the Nationwide Inpatient Sample (NIS) between 2002 and 2012. Multivariable logistic regres-
sion was used to evaluate the association between HIV infection and in-hospital death after AMI or stroke.
Results. Overall, 18 369 785 AMI/stroke hospitalizations were included in the analysis. Patients with a history of AIDS were sig-
nificantly more likely than uninfected patients to die during hospitalization after admission for AMI or stroke (odds ratio, 3.03 [95%
confidence interval {CI}, 1.71–5.38] for AMI and 2.59 [95% CI, 1.97–3.41] for stroke). Additionally, patients with AIDS were more
likely than HIV-uninfected patients to be discharged to nonhospital inpatient facilities after admission for AMI (OR, 3.14 [95% CI,
1.72–5.74]) or stroke (OR, 1.45; 95% CI, 1.12–1.87). There was a minimal difference in either outcome between HIV-infected pa-
tients without a history of AIDS and uninfected patients.
Conclusions. Patients with a history of AIDS were significantly more likely than uninfected patients to die during hospitalization
after admission for AMI or stroke. This disparity was not observed when infected patients without a history of AIDS were compared
to uninfected patients, implying that preserving immune function may improve cardiovascular outcomes in HIV-infected persons.
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Cardiovascular disease (CVD) is now one of the leading causes
of death in human immunodeficiency virus (HIV)–infected pa-
tients in the United States [1–4]. HIV-infected patients are at
higher risk for acute myocardial infarction (AMI) than unin-
fected patients, even after adjustment for traditional CVD risk
factors [2–4]. This increased risk of CVD may be linked to the
severity of HIV-associated immunosuppression. For example, a
recent study found no significant difference in the incidence of
AMI among uninfected patients and patients with less advanced
HIV infection [3]. By contrast, little is known about the relation-
ship between severity of HIV infection and clinical outcomes in
patients with AMI or stroke. The current study examined the in-
hospital outcomes of AMI and stroke in patients with a history of
AIDS, HIV-infected patients without a history of AIDS, and
uninfected patients. To accomplish this goal, we used the Nation-
wide Inpatient Sample (NIS), a registry of billing data for >87
million all-payer hospitalizations in the United States.
METHODS
Data Source and Case Ascertainment
Hospital discharge data were obtained from the 2002–2012 NIS,
a component of the Healthcare Cost and Utilization Project
produced by the Agency for Healthcare Research and Quality.
The NIS is an all-payer data set including records for approxi-
mately 20% of nonfederal inpatient discharges in the United
States [5]. Survey weights are provided with the NIS to enable
estimation of national trends in inpatient hospitalizations.
Data provided on the NIS include demographic characteristics
(age, sex, and race), primary payer, diagnosis and procedure
codes, length of stay, discharge disposition, and inpatient char-
ges. Admissions associated with HIV infection were identified
on the basis of the presence of International Classifications of
Disease, Ninth Edition, Clinical Modification (ICD-9-CM) diag-
nosis code 042 (“human immunodeficiency virus”) and V08
(“asymptomatic HIV”) listed at any position in the claim [6].
The 042 code is reserved for patients who have ever had a doc-
umented HIV-related illness or met clinical criteria for AIDS
Received 29 October 2015; accepted 23 February 2016; published online 3 March 2016.
aPresent affiliation: Department of Gynecology and Obstetrics, Johns Hopkins University
School of Medicine, Baltimore, Maryland.
Correspondence: N. L. Okeke, Department of Medicine, Division of Infectious Diseases, Duke
University Medical Center, Hanes House, Rm 154, 315 Trent Dr, Durham, NC 27710 (lance.
okeke@duke.edu).
The Journal of Infectious Diseases® 2016;213:1955–61
© The Author 2016. Published by Oxford University Press for the Infectious Diseases Society
of America. All rights reserved. For permissions, e-mail journals.permissions@oup.com.
DOI: 10.1093/infdis/jiw082
CVD-Associated Hospital Outcomes in HIV-Infected Patients • JID 2016:213 (15 June) • 1955
and is thus a surrogate indicator of current or prior severe HIV-
related immunosuppression. In the current study, patients with
a history of AIDS were identified by an ICD-9-CM code of 042,
while patients with chronically asymptomatic HIV infection
were identified by the ICD-9-CM billing code of V08. All pa-
tients with a reported ICD-9-CM diagnosis code of 410.00–
410.92 for AMI and of 430.00–434.91 for stroke in either the
first or second diagnosis code listed on the claim were identified
for inclusion in the analysis. The primary outcome of interest
was all-cause in-hospital mortality. Other outcomes of interest
were posthospitalization discharge to a nonhospital inpatient
facility (ie, a skilled nursing facility, an inpatient rehabilitation
facility, a long-term acute care hospital, or an intermediate care
facility) and length of hospital stay.
Statistical Analysis
Unadjusted comparisons between patient characteristics and
outcomes were calculated using weighted linear and logistic
regression. Adjusted associations between HIV status and out-
comes were evaluated using weighted logistic, negative binomi-
al, and gamma log-link regressions as appropriate. The data set
was constructed using SAS System, version 9.4 (SAS Institute,
Cary, North Carolina), with analyses performed using Stata/
MP, version 14.0 (StataCorp, College Station, Texas). Reported
odds ratios (ORs) were adjusted for a number of patient-level
factors, including age, sex, race/ethnicity, insurance status, hos-
pital size, hospital with academic affiliation, urban versus rural
hospital, hospital region, tobacco use, substance abuse, and co-
morbid medical conditions. To more easily evaluate the find-
ings, the adjusted results are also presented as incremental
effects. A 2-sided α level of 0.05 was considered statistically sig-
nificant. Authorization for this study and a waiver of informed
consent was obtained from the University of North Carolina–
Chapel Hill Institutional Review Board.
RESULTS
AMI Hospitalization Outcomes by HIV Status
Between 2002 and 2012, 8 233 608 AMI hospitalizations and
10 136 177 stroke hospitalizations occurred in the United States,
based on weighted estimates of inpatient admissions included in
the NIS database (Table 1). Of these hospitalizations, 48 933
had a billing diagnosis code for HIV (21 117 AMI-associated
hospitalizations and 27 816 stroke-associated hospitalizations).
HIV-infected patients hospitalized for AMI were significantly
younger than uninfected patients (51.8 years vs 68.5 years;
P≤ .001). There was also a higher proportion of black individ-
uals (39.1% vs 9.5%; P < .001) and lower proportion of females
(19.2% vs 41.3%; P < .001) in the HIV-infected group. During
the study period, the overall number of hospitalizations for
AMI decreased by 12%, but it increased by 21% among patients
with a history of AIDS and by 83% among HIV-infected pa-
tients without a history of AIDS (P≤ .001 for trend; Figure 1).
AMI hospitalizations were longer among patients with a his-
tory of AIDS. After adjustment for patient and facility level fac-
tors, the duration of AMI-associated inpatient admissions in
patients with a history of AIDS was 4.1 days longer than for un-
infected patients (95% confidence interval [CI], 2.0–6.3 days;
P < .001; Figure 2). By contrast, the duration of hospitalizations
for AMI for patients without a history of AIDS was shorter
(adjusted difference, −0.8 days; 95% CI, −.6 to −1.0 days;
P < .0001) than that of uninfected patients. Patients with a his-
tory of AIDS were also significantly more likely to be discharged
to nonhospital inpatient facilities after hospitalization than un-
infected patients (OR, 3.14; 95% CI, 1.72–5.74). However, there
was no significant difference in the likelihood of discharge to a
nonhospital inpatient facility following hospitalization for AMI
among HIV-infected persons without a history of AIDS and
uninfected patients (OR, 0.91; 95% CI, .73–1.14). Overall, pa-
tients with a history of AIDS hospitalized for AMI were signifi-
cantly more likely to die during admission than uninfected
patients (OR, 3.03; 95% CI, 1.71–5.38; P < .001). However,
there was no significant difference in the odds of in-hospital
death for AMI-associated hospital admissions between HIV-
infected persons without a history of AIDS and uninfected
patients (OR, 0.80; 95% CI, .63–1.02).
Stroke Hospitalization Outcomes, by HIV Status
HIV-infected patients hospitalized for stroke were significantly
younger than uninfected patients admitted for the same diag-
nosis (age, 51.0 years vs 70.1 years; P < .001; Table 1). Similar to
AMI-associated hospitalizations, there was also a higher pro-
portion of black individuals (56.8% vs 14.6%; P < .001) and a
lower proportion of females (19.2% vs 31.3%; P < .001) in the
HIV-infected group. Although the overall number of stroke
hospitalizations increased in the entire population over the
study period (2002–2012), the number of stroke hospitaliza-
tions increased more rapidly among HIV-infected patients
over the study period (Figure 1).
When hospitalized for stroke, patients with a history of AIDS
remained in the hospital longer than uninfected patients. After ad-
justment for patient-level factors, stroke-associated hospitaliza-
tions among patients with a history of AIDS were 30% longer
than those of uninfected patients (adjusted difference, 1.8 days;
95%CI, .8–2.7 days;P < .001; Figure 3). However, stroke-associated
hospitalizations among HIV-infected patients without a history of
AIDSwereactuallyslightlyshorter than thoseofuninfectedpatients
(adjusted difference,−0.4 days; 95% CI, −.1 to −.7 days).
Stroke-associated hospitalizations among patients with a his-
tory of with AIDS were also more likely to result in discharge to
a nonhospital inpatient facility than those of uninfected patients
(OR, 1.45; 95%CI, 1.12–1.87; Table 2). By contrast,HIV-infected
persons without a history of AIDS were only slightly more likely
to be discharged to nonhospital inpatient care than uninfected
patients (OR, 1.11; 95% CI, 1.01–1.23). After adjustment for
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Table 1. Demographic and Clinical Characteristics of Persons With Primary Hospital Diagnoses of Acute Myocardial Infarction (AMI) and
Cerebrovascular Accident (CVA), Nationwide Inpatient Sample, 2002–2012
AMI-Associated Hospitalizations, by Presence of HIV Code on Claim
(n = 1 736 422; Weighted n = 8 233 608)
CVA-Associated Hospitalizations, by Presence of HIV Code on Claim
(n = 2 139 851; Weighted n = 10 136 177)
Characteristic
No (n = 1 731 608
Weighted
n = 8 210 777)
Yes
No (n = 2 133 477;
Weighted
n = 10 106 142)
Yes
History of AIDS
(n = 2 443; Weighted
n = 11 591)
No History of AIDS
(n = 2 371; Weighted
n = 11 240)
History of AIDS
(n = 2 807; Weighted
n = 13 412)
No History of AIDS
(n = 3 567; Weighted
n = 16 893)
Age, y
Overall 68.5 ± 14.4 51.7 ± 9.4a 51.9 ± 9.5a 70.1 ± 14.9 52.3 ± 10.7a 49.5 ± 11.0a
≥50 y 7 323 194 (89.2) 6855 (59.1)a 6535 (58.1)a 9 183 215 (90.9) 8272 (61.7)a 8411 (49.8)a
Female sex 3 418 078 (41.6) 2258 (19.5)a 2114 (18.8)a 5 270 547 (52.2) 4264 (31.8)a 5208 (30.8)a
Race
White 5 010 877 (77.6) 4423 (44.9)a 4439 (44.7)a 5 835 978 (72.3) 3165 (26.7)a 4215 (28.2)a
Black 611 874 (9.5) 3906 (39.6)a 3839 (38.7)a 1 177 259 (14.6) 6879 (58.0)a 8382 (56.0)a
Hispanic 462 718 (7.2) 960 (9.7) 1084 (10.9) 600 602 (7.4) 1274 (10.7) 1787 (11.9)
Asian/PI 135 875 (2.1) 32 (0.3)a 63 (0.6)a 208 805 (2.6) 53 (0.4)a 102 (0.7)a
Native American 33 808 (0.5) 29 (0.3) 48 (0.5) 37 949 (0.5) 30 (0.3) 83 (0.6)
Other 198 754 (3.1) 562 504 (5.1) 451 (4.5) 212 737 (2.6) 461 (3.9) 399 (2.7)
Primary payer
Medicare 4 915 146 (60.0) 4027 (34.8)a 5124 (45.7) 6 713 155 (66.5) 4752 (35.6)a 6025 (35.7)a
Medicaid 442 605 (5.4) 2556 (22.1)a 2750 (24.5)a 666 102 (6.6) 4243 (31.8)a 6017 (35.7)a
Private 2 173 902 (26.5) 3469 (30.0) 2295 (20.5) 2 083 863 (20.7) 2634 (19.7) 3068 (18.2)
Self-pay 418 839 (5.1) 934 (8.1) 669 (6.0) 375 938 (3.7) 1046 (7.8) 1142 (6.8)
No charge 38 495 (0.5) 156 (1.4)a 39 (0.3) 36 808 (0.4) 199 (1.5)a 134 (0.8)
Facility size, based on no. of beds
Small 830 921 (10.2) 804 (7.0) 703 (6.3) 1 070 546 (10.6) 928 (7.0) 1183 (7.0)
Medium 1 968 215 (24.1) 2831 (24.6) 2527 (22.6) 2 364 164 (23.5) 3126 (23.4) 3711 (22.1)
Large 5 376 422 (65.8) 7865 (68.4) 7947 (71.1) 6 624 814 (65.9) 9292 (69.6) 11 888 (70.8)
Hospital geographic region
Northeast 1 673 022 (20.4) 3400 (29.3) 3233 (28.8) 1 835 246 (18.2) 4047 (30.2) 4343 (25.7)
Midwest 1 901 460 (23.2) 1479 (12.8) 1309 (11.7) 2 391 689 (23.7) 1738 (13.0) 1751 (10.4)
South 3 269 773 (39.8) 5888 (50.8) 4904 (43.6) 4 063 608 (40.2) 6997 (52.2) 8073 (47.8)
West 1 366 523 (16.6) 824 (7.1)a 1793 (16.0) 1 815 869 (18.0) 631 (4.7)a 2725 (16.1)
Urban hospital
facility
7 201 216 (88.1) 11 073 (96.3) 10 768 (96.4) 8 825 329 (87.7) 12 940 (97.0) 16 246 (96.8)
Hospital with
teaching affiliation
3 675 357 (45.0) 7415 (64.5)a 7306 (65.4)a 4 609 401 (45.8) 9013 (67.5)a 11 446 (68.2)a
Calendar periodb
2002–2005 3 117 511 (38.0) 3655 (32.5) 3588 (31.0) 3 429 110 (34.0) 5073 (30.1) 3293 (24.6)
2006–2009 2 919 823 (35.6) 4033 (35.9) 4158 (36.0) 3 697 864 (36.5) 6471 (38.3) 5081 (37.9)




2 601 977(31.7) 1918 (16.5) 2712(24.1) 1 159 431 (11.5) 907 (6.8) 1080 (6.4)
Peripheral vascular
disease
783 708 (9.5) 621 (5.4) 577 (5.1) 920 185 (9.1) 690 (5.1) 637 (3.8)a
Hypertension 5 244 570 (63.9) 6674 (57.6) 6170 (54.9) 7 340 040 (72.6) 8718 (65.0) 8499 (50.3)a
COPD 1 685 308(20.5) 1792 (15.5) 1932 (17.2) 1 488 899 (14.7) 1873 (14.0) 2195 (13.0)
Diabetes 2 598 395 (31.7) 2531 (21.8) 2496 (22.2) 2 957 299 (29.2) 3298 (24.5) 2853 (16.9)
Obesity 713 065 (8.7) 458 (3.9) 397 (3.5) 552 971 (5.5) 428 (3.2) 263 (1.6)a
Alcohol abuse 205 938 (2.5) 613 (5.3) 613 (5.5) 321 315 (3.2) 941 (7.0) 1277 (7.6)
Substance abuse 137 766 (1.7) 2008 (17.3)a 2177 (19.4)a 162 865 (1.6) 2310 (17.2)a 3165 (18.7)a
Current smoker 1 534 799 (18.6) 4755 (41.0)a 3239 (28.8) 1 222 506 (12.1) 3259 (24.3) 3406 (20.2)
Former smoker 707 272 (8.3) 782 (6.7) 735 (6.5) 765 153 (7.6) 635 (4.7) 632 (3.7)
Hyperlipidemia 885 542 (10.8) 1 394 (12.0) 905 (8.0) 1 016 958 (10.1) 853 (6.4) 592 (3.5)a
Data are no. (%) of hospitalizations or mean value ±SD.
Abbreviations: COPD, chronic obstructive pulmonary disease; HIV, human immunodeficiency virus; PI, Pacific Islander.
a Statistically and practically significantly different from the uninfected group (P < .001 and Cohen d> 0.5, respectively).
b Percentages represent the proportion of total hospitalizations that occurred in the designated period.
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risk factors, patients with a history of AIDS had a significantly
higher risk for in-hospital mortality after a stroke than uninfect-
ed patients (OR, 2.59; 95% CI, 1.97–3.41; P < .001) Similar to
our observations for AMI, there was no significant difference
in the likelihood of in-hospital mortality after stroke between
infected patients without a history of symptomatic disease
and uninfected patients (OR, 1.14; 95% CI, .98–1.33).
DISCUSSION
This study documents an association between a history of HIV-
induced immunosuppression and outcomes of major CVD
events. Patients with a history of AIDS who were hospitalized
for either AMI or stroke had a significantly higher risk of in-
hospital mortality, a significantly higher likelihood of discharge
to nonhospital inpatient facilities, and a significantly longer
length of stay than uninfected patients. By contrast, the out-
comes of HIV-infected patients without a history of AIDS
were similar to those of uninfected patients. This observation
is important because CVD is now one of the leading causes
of death among patients with chronic HIV infection and be-
cause antiretroviral therapy can dramatically improve HIV-
induced immunosuppression [7]. These findings are also timely
given the results of the recently published Strategic Timing of
Antiretroviral Therapy trial, which indicate that even mild levels
of HIV-induced immunosuppression (eg, a CD4+ T-cell count
of 350 cells/mm3) adversely affects risk for non–AIDS-related
outcomes [8].
Our study increases the understanding of non–AIDS-related
clinical consequences of chronic HIV infection. We found that
HIV-infected patients who developed AMI or stroke were more
than twice as likely to die during hospitalization as uninfected
patients with the same CVD event and that most of this mor-
tality risk was borne by patients with a history of AIDS. Clari-
fying the disproportionate distribution of CVD-associated risk
among HIV-infected patients is important because of the grow-
ing overlap between the 2 epidemics. Given that over half of
Figure 1. Trends in hospitalizations for acute myocardial infarction and cerebrovascular accident, by human immunodeficiency virus (HIV) claim code, Nationwide Inpatient
Sample, 2002–2012. Abbreviations: AMI, acute myocardial infarction; CVA, cerebrovascular accident.
Figure 2. Adjusted values for major outcome metrics for acute myocardial infarction–associated hospitalizations, by human immunodeficiency virus (HIV) diagnosis code,
Nationwide Inpatient Sample, 2002–2012. All point estimates were adjusted for age, sex, race/ethnicity, insurance status, hospital size, hospital with academic affiliation,
urban versus rural hospital, hospital region, tobacco use, substance abuse, and comorbid medical conditions.
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HIV-infected patients living in the United States will be aged
≥50 years by 2017 [9], the number of HIV-infected patients
with CVD will continue to climb. The precipitous increase in
the number of hospitalizations for AMI and stroke among
HIV-infected patients over the study period (Figure 1) are a
likely manifestation of the rapid aging of this population [10].
Thus, there is an urgent need to improve our understanding of
CVD in this population.
Exposure to HIV-induced immunosuppression has been
linked to an increased risk of many non–AIDS-related condi-
tions [11–14]. Nadir CD4+ T-cell counts of <350 cells/mm3
are associated with surrogates of atherosclerosis [15, 16], includ-
ing increased carotid intima-media thickness and decreased ar-
terial compliance (indicated by flow-mediated dilatation). Low
nadir CD4+ T-cell counts have also been associated with in-
creased levels of the inflammatory marker interleukin 6 [17],
sustained hypertension, and left ventricular hypertrophy [18,
19]. These findings of adverse vascular physiology associated
with severe HIV-induced immunosuppression appear to cor-
roborate with published clinical experience. For example, 2
large studies of the Northern California Kaiser Permanente
cohort showed that HIV-infected patients with a CD4+ T-cell
count of ≤200 cells/mm3 had a 74% higher incidence of AMI
and a 60% higher incidence of stroke than uninfected patients.
Interestingly, there was no significant difference between the in-
cidence rate of AMI and stroke in HIV-infected cohort mem-
bers with nadir CD4+ T-cell counts of ≥500 cells/mm3 and
uninfected patients [3, 20]. The current study provides a
key finding by linking the prognosis of HIV-infected patients
with AMI or stroke to the patient’s level of HIV-associated
immunosuppression.
In 2012, the Department of Health and Human Services rec-
ommended treatment of all HIV-infected persons regardless of
CD4+ T-cell count, a recommendation adopted by the World
Health Organization in September 2015 [21, 22]. With full im-
plementation of these guidelines, one can anticipate that more
HIV-infected persons will initiate ART before the onset of ad-
vanced HIV-related immunosuppression and the deleterious
implications on cardiovascular health associated with it. Our
analysis presents evidence supporting the suggestion that the
implementation of these guidelines alone will greatly improve
AMI-related and stroke-related mortality among HIV-infected
Figure 3. Adjusted values for major outcome metrics for stroke-associated hospitalizations, by human immunodeficiency virus (HIV) diagnosis code, Nationwide Inpatient
Sample, 2002–2012. All point estimates were adjusted for age, sex, race/ethnicity, insurance status, hospital size, hospital with academic affiliation, urban versus rural hos-
pital, hospital region, tobacco use, substance abuse, and comorbid medical conditions.
Table 2. Adjusted Estimates for Major Hospitalization Outcome Metrics in Patients Hospitalized for Acute Myocardial Infarction (AMI) and
Cerebrovascular Accident (CVA), by Human Immunodeficiency Virus (HIV) Status, Nationwide Inpatient Sample, 2002–2012
HIV Status, by Outcome Death, ORa (95% CI) Nonhospital Institutional Care, ORa (95% CI) Length of Stay Ratiob (95% CI)
AMI-associated hospitalization
History of AIDS 3.03 (1.71–5.38)c 3.14 (1.72–5.74)c 1.76 (1.41–2.19)c
HIV without history of AIDS 0.80 (.63–1.02) 0.91 (.73–1.14) 0.85 (.82–.88)c
CVA-associated hospitalization
History of AIDS 2.59 (1.97–3.41)c 1.45 (1.12–1.87)c 1.31 (1.15–1.48)c
HIV w/o history of AIDS 1.14 (.98–1.33) 1.12 (1.01–1.23)c 0.93 (.87–.99)c
All point estimates were adjusted for age, sex, race/ethnicity, insurance status, hospital size, hospital with academic affiliation, urban versus rural hospital, hospital region, tobacco use,
substance abuse, calendar year, and comorbid medical conditions.
Abbreviations: CI, confidence interval; CVA, cerebrovascular accident; HIV, human immunodeficiency virus; OR, odds ratio.
a Reference is no HIV infection.
b Reference is length of stay for uninfected patients with a diagnosis.
c Statistically and practically significantly different from the uninfected group (P < .001 and Cohen d> 0.5, respectively).
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patients in the years ahead. At the very least, our study adds to
the growing body of evidence that CVD in infected persons
without a history of AIDS (ie, those with preserved immune
function) may be more similar to CVD in uninfected patients
than previously recognized.
Our study has limitations. The use of billing codes renders
our data subject to the accuracy of local billing practices of in-
dividual health systems. However, the size of our registry (>18
million hospitalizations) likely addresses the influence of severe
outliers. Owing to the use of billing data, we are also unable to
differentiate between hospitalizations that occurred in patients
with active AIDS and asymptomatic patients with a history of
AIDS. We also did not have access to CD4+ T-cell count,
HIV-1 load, or treatment status (or history or antiretroviral ex-
posure) at the time of hospitalization. Although data on longi-
tudinal CD4+ T-cell counts were not available for purposes of
this analysis, given the association between AIDS and low
CD4+ T-cell counts, we believe that the billing code for AIDS is
a surrogate for a low nadir CD4+ T-cell count, and we can pos-
tulate that patients with a billing code for AIDS had lower nadir
CD4+ T-cell counts than patients with a billing code for HIV
infection overall. We also acknowledge that, although admission
rates per population would be better indicator of population-
adjusted hospitalization rates, obtaining an exact enumeration
of HIV-infected persons in the United States (and persons
with AIDS) at any given time point is not feasible. Finally, we
did not have access to indicators of patient acuity on presenta-
tion, and thus a potential confounder related to inpatient prog-
nosis was not addressed by our analysis.
In summary, our study demonstrates that patients with a
history of AIDS hospitalized for AMI or stroke have a longer
inpatient length of stay, are more likely to be discharged
to nonhospital inpatient care, and are significantly more
likely to die while hospitalized than uninfected patients. By
contrast, there is no significant difference in AMI- and
stroke-associated hospital outcomes between HIV-infected
persons without a history of AIDS and uninfected patients.
Future studies are needed to confirm these findings and to
better understand their biological basis. In the meantime,
our data add further support for the importance of early
initiation of antiretroviral therapy in improving non–AIDS-
related outcomes in patients living with HIV.
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